ASGCT–FDA Liaison Meeting

View summaries

Sharing Our Members’ Expertise With FDA

The annual ASGCT–FDA Liaison Meeting is an opportunity for our subject matter expert members to engage directly with FDA staff. Each year Society presenters share information about the key challenges and new opportunities facing the field. In return, FDA provides a presentation relevant to ASGCT members’ interests.

Annual Liaison Meeting Presentations

2022

ASGCT reviewed FDA’s adoption of prior Society recommendations & opportunities for use of novel engineered AAV capsids in GT development. FDA provided an update on RMAT and OTAT operations.

2021

ASGCT discussed AAV-based GTs, including integration/insertion considerations & PNS ganglia toxicities, and CMC expectations for CGT products. FDA discussed the CBER/OTAT Growth Program.

2020

ASGCT made recommendations on immunogenicity testing, risk assessment for animal models and nonclinical data, & innovative clinical study design. FDA discussed a range of GT development challenges.

2019

ASGCT shared recommendations on surrogate endpoints & discussed comparability for pre- and post-marketing manufacturing changes. FDA discussed common GT IND deficiencies.

2018 Inaugural Meeting

ASGCT discussed RCL and RCR testing drug product, off-target effects in gene editing, manufacturing considerations, and LTFU for lentiviral vectors. FDA shared information about the RMAT designation.

2024

Register for the 27th Annual Meeting

May 7-11, 2024 | Baltimore, MD